Monday, October 2, 2023
Monday, October 2, 2023

Contact: 561.316.3330

3M and Rad AI Team Up to Offer Rad AI’s Advanced Technology for Generating Customized Radiology Reporting. More on this and details at RSNA 2020

3M Health Information Systems and Rad AI have teamed up to offer Rad AI’s advanced technology for generating customized radiology report impressions integrated with 3M™ M*Modal Fluency for Imaging, 3M’s complete radiology reporting and workflow management solution.

By building on the artificial intelligence (AI) capabilities of both companies, 3M and Rad AI will further streamline the reporting process, yielding substantial time savings for radiologists, alleviating burnout, and creating more time to focus on patient care.

“Rad AI and 3M share a common goal of helping radiology teams become stronger and more resilient in the face of growing demand, complex regulations and increased competition,” said Dr. Jeff Chang, ER radiologist and Rad AI co-founder. “Working together, we can streamline radiology workflows so radiologists experience less burnout and can enjoy their daily practice to the fullest.” According to Chang, radiologists can experience total time savings of up to 24 percent by using Rad AI software to automatically generate customized report impressions as part of their standard speech-driven reporting workflow.

3M Health Information Systems and Rad AI will demo the integrated workflow at RSNA 2020, the annual conference of the Radiological Society of North America which is scheduled for Nov. 29 – Dec. 5 in a virtual format.

Enhanced with computer-assisted physician documentation (CAPD) technology, 3M Fluency for Imaging offers proactive, real-time clinical insights to radiologists, helping them close gaps in clinical documentation. Accurate documentation and coding are a critical focus for radiology practices given major changes to Evaluation and Management (E/M) Services coding scheduled for January 2021.

Abercrombie Radiology, an imaging services provider with 25 radiologists in Knoxville, TN, is using 3M Fluency for Imaging integrated with the 3M™ CodeAssist™ System for professional fee coding to promote coding compliance and accurate reimbursement. In a pilot of automated CAPD nudges for just three coding concepts, radiologists were able to capture greater documentation specificity for a projected annualized financial impact of $150,000 in increased reimbursement.

“Like all radiology practices, keeping pace with changing regulations is important to our financial health,” said Shannon Hampson, chief executive officer of Abercrombie Radiology. “3M M*Modal technology helps our radiologists document the full patient story in real-time, during their standard reporting workflow. We avoid back-end coding queries and corrections so our radiologists can focus on patient care. And it gives us confidence that our coding and reimbursement is as accurate as possible.”

Ranked #1 KLAS Category Leader, Front-End Speech Recognition, Imaging for 2020, 3M Fluency for Imaging combines advanced front-end speech recognition technology and integrated productivity enhancing tools for faster creation of higher quality diagnostic interpretations. Additionally, 3M™ M*Modal Scout provides AI-powered analytics that help monitor and improve overall clinical and business outcomes.

3M Health Information Systems is a division of 3M Health Care, part of 3M Company. For more information about the 3M M*Modal Fluency for Imaging, visit www.3m.com/his.

Source3M
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Ariceum Therapeutics’ Targeted Radiopharmaceutical 177Lu-satoreotide Exhibits Promising Clinical Response and Good Tolerability Profile in Patients with Advanced Neuroendocrine Tumours

Satoreotide combines Ariceum’s proprietary peptide satoreotide - a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SSTR2) - with the radioactive isotope ‘payload’ 177Lutetium. SSTR2 is a cell surface protein often overexpressed in certain cancers, including NETs and small cell lung cancer (SCLC).

New Hot Start Isothermal Mixes Boost Sensitivity, Specificity, and Speed of DNA Target Detection

Isothermal mixes are important in a range of isothermal amplification applications, including whole genome amplification, point-of-care assay development and testing, and strand displacement amplification for synthetic biology. However, a common issue with isothermal mixes is non-specific amplification — where primers bind to unintended DNA targets — because amplification often takes place at a fixed temperature which may favour non-specific primer interactions, contrary to PCR. Isothermal mixes can also lead to primer dimer formation, where primers associate with each other and are extended by the polymerase.

Branded Legacy Invests Heavily in Innovation and Growth with $540,000 Expansion

This strategic initiative underscores Branded Legacy's unwavering commitment to innovation, quality, and customer satisfaction. The expansion project is set to infuse over $500,000 worth of inventory into the company, reinforcing its position as a leader in the market.

Cue Biopharma Completes Patient Enrollment in Ph1b Head & Neck Cancer Trial

“Completing the enrollment of the recommended phase 2 dose patient expansion cohort is an important milestone as the data from this trial guides further development plans and associated discussions with the Food and Drug Administration (FDA),” said Daniel Passeri, chief executive officer of Cue Biopharma.

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

Michelle Fraser, head of cell and gene therapy at Revvity, underscores the importance of providing broad access to this technology: "Base editing has been extensively demonstrated in numerous studies to safely and precisely control the correction of single base changes at multiple target sites, simultaneously. This streamlined approach simplifies complex multi-gene editing, holding great promise for the development of new cell therapies targeting rare inherited genetic diseases, cancer, and in the creation of universal donor cells as the foundation of allogeneic cell therapies."

By using this website you agree to accept Medical Device News Magazine Privacy Policy